In a mouse colitis model, target colon exposures with minimal systemic exposure were successfully achieved with 2 when dosed at 30 mg/kg (active parent-dose equivalent) BID, however only a moderate pharmacodynamic effect, measured as a reduction of IBA1+ macrophages in the colon, was observed. Here, AIF1 is linked to colitis.